A Phase 2 interventional study of Desloratadine 2.5 mg and Oxybutynin 2.5 mg in Post-nasal Drip, Seasonal Allergic Rhinitis and Rhinorrhea, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-16.
Sponsored by Organon and Co · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal — none open to participants now, none under way, none of them phase 3. desloratadine · Rhinitis, Allergic, Seasonal.
Among the 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal, this one is the 3rd largest by enrollment, is the only one that started in 2005, is the only one in phase 2, and was the 8th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
desloratadine: first FDA approval 2001 (CLARINEX), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 540 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 272 across the 10 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
This study is registered under Organon and Co, one of the names counted as Organon & Co.. Under that name alone:
Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.
37 studies in Rhinitis, Allergic, Seasonal by Organon & Co.: none open now, none under way, none of them phase 3. Of 37 finished, 21 (57%) have results posted.
Among the 37 studies in Rhinitis, Allergic, Seasonal by Organon & Co., this one is the 14th largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2005, is one of 2 in phase 2, and was the 24th registered.
Organon & Co.’s Rhinitis, Allergic, Seasonal studies by the year they started, since 1993.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing desloratadine in Rhinitis, Allergic, Seasonal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Organon & Co.’s 37 in Rhinitis, Allergic, Seasonal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was a 1-week study of desloratadine (DL) plus oxybutynin (OXY) at two dose levels in the treatment of post-nasal drip in participants with seasonal allergic rhinitis. Participants received either desloratadine twice a day, oxybutynin twice a day, desloratadine plus lower-dose oxybutynin twice a day, desloratadine plus higher-dose oxybutynin twice a day, or placebo for 7 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must:
Exclusion Criteria:
Subjects who have:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Desloratadine 2.5 mg twice daily (BID) + Placebo for Oxybutynin 2.5 mg BID for 7 days
Drug: Desloratadine 2.5 mg · Drug: Placebo for Oxybutynin 2.5 mg
Placebo for Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
Drug: Oxybutynin 2.5 mg · Drug: Placebo for Desloratadine 2.5 mg
Desloratadine 2.5 mg BID + Oxybutynin 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
Drug: Desloratadine 2.5 mg · Drug: Oxybutynin 2.5 mg · Drug: Placebo for Oxybutynin 2.5 mg
Desloratadine 2.5 mg BID + Oxybutynin 5 mg BID for 7 days
Drug: Desloratadine 2.5 mg · Drug: Oxybutynin 2.5 mg
Placebo for Desloratadine 2.5 mg BID + Placebo for Oxybutynin 2.5 mg BID for 7 days
Drug: Placebo for Desloratadine 2.5 mg · Drug: Placebo for Oxybutynin 2.5 mg
Desloratadine 2.5 mg BID
Also known as: SCH 034117, Clarinex
Oxybutynin 2.5 mg BID
Also known as: Ditropan
Placebo BID
Placebo BID
Change from baseline in mean daily AM/PM Prior post-nasal drip scores averaged over the entire treatment period
Time frame: Days 1 to 7 +/- 2 days
Anterior rhinorrhea averaged over Days 1 to 8
Time frame: Days 1 to 8
No study locations are listed for this record.
The record gives a start of Apr 2005, a primary completion of Jun 2005 and a completion of Jun 2005. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Desloratadine · Oxybutynin
Rhinitis, Allergic, Seasonal →